Literature DB >> 16897175

Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide.

Reiko T Lee1, Yuan C Lee.   

Abstract

Binding of carbohydrate ligand by human C-reactive protein (CRP), in both native form and structurally deviated form (neoCRP or mCRP), was investigated using galactose-6-phosphate (Gal6P)- and Galbeta3GalNAc-containing bovine serum albumin (BSA) derivatives. To this end, we synthesized glycosides of Gal6P and Galbeta3GalNAc that can potentially generate a terminal aldehyde group. omega-Aldehydo glycosides were then conjugated to BSA via reductive amination. Using these neoglycoproteins, we showed that: (1) Gal6P-BSA and Galbeta3GalNAc-BSA bound to both forms of CRP, the former with or without calcium and the latter only in the absence of calcium; (2) phosphate-containing ligands can be bound with or without calcium, but the binding is much stronger in the presence of calcium than in the absence, underscoring the importance of direct coordination of phosphate to two calcium ions observed in the X-ray structure of phosphorylcholine (PC)-CRP complex; (3) cross-inhibition studies further corroborated the hypothesis that binding sites of PC and sugar are contiguous; (4) while PC-BSA bound to the native CRP over a wide pH range of 4.5 to 9, all the carbohydrate ligands and protamine-BSA (poly-cation-based ligand) exhibited optimal binding at around pH 6 to 6.5; and (5) ligand-binding conformation of mCRP appears to be more fragile than that of the native CRP in the acidic media (pH < 6).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897175     DOI: 10.1007/s10719-006-6173-x

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  32 in total

1.  Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit.

Authors:  L A Potempa; J N Siegel; B A Fiedel; R T Potempa; H Gewurz
Journal:  Mol Immunol       Date:  1987-05       Impact factor: 4.407

2.  Microheterogeneity of the carbohydrate group of aspergillus oryzae alpha-amylase.

Authors:  J F McKelvy; Y C Lee
Journal:  Arch Biochem Biophys       Date:  1969-06       Impact factor: 4.013

3.  Ligand-binding characteristics of rat serum-type mannose-binding protein (MBP-A). Homology of binding site architecture with mammalian and chicken hepatic lectins.

Authors:  R T Lee; Y Ichikawa; M Fay; K Drickamer; M C Shao; Y C Lee
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

Review 4.  Human C-reactive protein: expression, structure, and function.

Authors:  J E Volanakis
Journal:  Mol Immunol       Date:  2001-08       Impact factor: 4.407

5.  Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue.

Authors:  E E Diehl; G K Haines; J A Radosevich; L A Potempa
Journal:  Am J Med Sci       Date:  2000-02       Impact factor: 2.378

Review 6.  Binding of C-reactive protein to C-carbohydrate and PC-substituted protein.

Authors:  E C Gotschlich; T Y Liu; E Oliveira
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

7.  Degradation of a pneumococcal type-specific polysaccharide with exposure of group-specificity.

Authors:  J D Higginbotham; M Heidelberger; E C Gotschlich
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

8.  Europium as a label in time-resolved immunofluorometric assays.

Authors:  I Hemmilä; S Dakubu; V M Mukkala; H Siitari; T Lövgren
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

9.  Binding reactivity of C-reactive protein for polycations. II. Modulatory effects of calcium and phosphocholine.

Authors:  L A Potempa; J N Siegel; H Gewurz
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

10.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

View more
  7 in total

Review 1.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

Review 2.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

3.  C-reactive protein enhances activation of coagulation system and inflammatory response through dissociating into monomeric form in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Peng-cheng Xu; Shan Lin; Xiao-wei Yang; Dong-Mei Gu; Tie-kun Yan; Li Wei; Bao-li Wang
Journal:  BMC Immunol       Date:  2015-03-03       Impact factor: 3.615

Review 4.  Structure-Function Relationships of C-Reactive Protein in Bacterial Infection.

Authors:  Donald N Ngwa; Alok Agrawal
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

Review 5.  Human Lectins, Their Carbohydrate Affinities and Where to Find Them.

Authors:  Cláudia D Raposo; André B Canelas; M Teresa Barros
Journal:  Biomolecules       Date:  2021-01-29

6.  An epidemiological analysis of potential associations between C-reactive protein, inflammation, and prostate cancer in the male US population using the 2009-2010 National Health and Nutrition Examination Survey (NHANES) data.

Authors:  Catherine A St Hill; M Nawal Lutfiyya
Journal:  Front Chem       Date:  2015-08-28       Impact factor: 5.221

7.  The plasma level of mCRP is linked to cardiovascular disease in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kai-Li Wu; Qing-Hui Liang; Bin-Tao Huang; Na Ding; Bo-Wei Li; Jian Hao
Journal:  Arthritis Res Ther       Date:  2020-10-02       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.